{"product_id":"ultragenyx-business-model-canvas","title":"Ultragenyx  Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx Business Model Canvas - The strategic playbook for turning rare‑disease science into patient impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore a compact, actionable map of Ultragenyx's commercial strategy: value propositions, key partners, revenue models, and growth levers that convert enzyme replacement, gene, and small‑molecule innovations into sustainable, patient‑focused therapies. Quickly grasp where value is created, risks are managed, and opportunities to scale exist-designed to spark insights and invite deeper discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Commercial Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains a long-term commercial alliance with Kyowa Kirin for Crysvita, sharing launch and marketing costs and tapping Kyowa Kirin's global infrastructure; Crysvita net sales reached about $1.1bn in 2024, easing Ultragenyx's commercialization burden. By end-2025, partnerships expanded with regional distributors in Asia and Latin America, covering over 30 additional markets to speed uptake and reduce country-specific capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx partners with smaller biotechs and academia to in-license rare-disease candidates-e.g., the 2020 collaboration with Mereo BioPharma on setrusumab-keeping a pipeline across gene therapy and mRNA; by end-2025 Ultragenyx reported 25+ programs and ~$1.2B in R\u0026amp;D spend (2024 FY) supporting these deals. These collaborations use milestone payments and tiered royalties to align incentives toward successful trials and approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CDMO Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains in-house manufacturing but contracts specialized CDMOs for modalities and scale; these partners supply technical expertise and GMP capacity to produce complex biologics and gene therapies under strict FDA\/EMA standards.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025, CDMO relationships were central to scaling recently approved gene therapies-company disclosures and filings cite multi‑site CDMO capacity expansions aimed to meet projected global demand of tens of thousands of doses and support revenue targets in the low hundreds of millions by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx partners with groups like EveryLife Foundation for Rare Diseases and disease-specific organizations to shape trial recruitment and regulatory strategy, using patient-journey insights to guide development; in 2024 Ultragenyx cited patient-group collaboration in 18+ trials and reported a 27% faster enrollment versus industry benchmarks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18+ trials in 2024 involved patient-group support\u003c\/li\u003e\n\u003cli\u003e27% faster enrollment vs industry norms (2024)\u003c\/li\u003e\n\u003cli\u003eInsights used for IND\/ NDA strategy and endpoint selection\u003c\/li\u003e\n\u003cli\u003eEnsures product features match rare-disease patient needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider and Institutional Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with specialized medical centers and academic hospitals enable Ultragenyx to run complex trials for ultra-rare diseases, accessing patient cohorts often numbering fewer than 100 and shortening enrollment by up to 30% versus broad-site models.\u003c\/p\u003e\n\u003cp\u003eThese sites provide primary data collection, help set diagnostic protocols, and have aided Ultragenyx in securing multiple regulatory designations-e.g., rare pediatric disease vouchers and 20+ orphan drug approvals through 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary trial sites for \u0026lt;100-patient cohorts\u003c\/li\u003e\n\u003cli\u003eEnrollment speed +30% vs broad sites\u003c\/li\u003e\n\u003cli\u003eContributed to 20+ orphan approvals (through 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: $1.1B Crysvita, 25+ pipeline partners, 30+ markets, 20+ orphan wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx leverages Kyowa Kirin and 30+ regional distributors for Crysvita (net sales ~$1.1B in 2024), CDMOs for GMP gene-therapy scale, 25+ partnered pipeline programs, patient-group ties speeding enrollment ~27%, and academic sites contributing to 20+ orphan approvals through 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eCrysvita sales\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eMarkets added\u003c\/td\u003e\n\u003ctd\u003e30+ (by end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e25+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eAnnual\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eFaster enrollment\u003c\/td\u003e\n\u003ctd\u003e+27% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eOrphan approvals\u003c\/td\u003e\n\u003ctd\u003e20+ (through 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Ultragenyx outlining customer segments, channels, value propositions, key resources and partners, cost and revenue structures, and go-to-market strategies aligned with its rare-disease biopharma operations and investor-ready presentation needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Ultragenyx's business model with editable cells, highlighting how rare-disease R\u0026amp;D, specialty partnerships, and orphan drug pricing relieve strategic and operational pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx advances discovery and clinical development across small molecules, enzyme replacement, and gene therapy, moving candidates from bench to dose-finding through rigorous preclinical work; R\u0026amp;D spend was about $660M in 2024 and was refocused to cut pipeline attrition by ~30% by end-2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs global, multi-site trials for ultra-rare diseases, coordinating regulators in 30+ countries and the FDA\/EMA to meet complex CMC and endpoint demands; their 2024 pipeline included 8 late-stage programs requiring cross-jurisdictional harmonization.\u003c\/p\u003e\n\u003cp\u003eThey design trials for tiny cohorts (often \u0026lt;50 patients), using natural history studies as external controls to boost power; for example, their 2023 burosumab-like programs cited historical-control effect sizes to achieve statistical significance with 20-40 patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Navigation and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx holds ongoing talks with FDA, EMA, and other agencies to secure orphan designations and fast-track status, supporting 2025 pipeline filings; preparing NDAs\/BLAs (e.g., 2024 BLA submission for vosoritide successor) requires extensive clinical and CMC data to prove safety and efficacy.\u003c\/p\u003e\n\u003cp\u003eMaintaining global manufacturing and safety-reporting compliance consumes large resources-Ultragenyx reported R\u0026amp;D and SG\u0026amp;A of $1.08 billion in FY2024-driving continuous updates to quality systems and pharmacovigilance across jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx runs advanced manufacturing at its Bedford, MA gene therapy site to produce high-quality AAV viral vectors and proteins, with 2025 yields improved to meet rising commercial and clinical demand.\u003c\/p\u003e\n\u003cp\u003eConsistency and purity are strict KPIs-batch deviation risks could harm patient safety and FDA\/EMA standing-so quality control and process validation are core operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBedford AAV\/vector facility\u003c\/li\u003e\n\u003cli\u003e2025 yield increases support commercial scale\u003c\/li\u003e\n\u003cli\u003eQC focuses on purity, potency, safety\u003c\/li\u003e\n\u003cli\u003eRegulatory compliance (FDA\/EMA) critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Launch and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx leads commercial launch and market access through physician education, payer negotiations, and logistics; in 2024 it reported $573M revenue, using outcomes data to secure coverage and pricing that support long-term access.\u003c\/p\u003e\n\u003cp\u003eA specialized rare-disease sales force targets ~1,200 expert clinicians globally, driving uptake while negotiating durable reimbursement terms with major US payers covering ~85% lives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician education: targeted outreach to ~1,200 experts\u003c\/li\u003e\n\u003cli\u003ePayer value: $573M 2024 revenue shows access wins\u003c\/li\u003e\n\u003cli\u003eDistribution: hub models ensure specialty logistics\u003c\/li\u003e\n\u003cli\u003eReimbursement: negotiated coverage across ~85% US lives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx ramps R\u0026amp;D and manufacturing-$660M spend, 8 late‑stage programs, 30% less attrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs end-to-end rare-disease R\u0026amp;D, global multi-site trials, and GMP AAV\/protein manufacturing, spending ~$660M on R\u0026amp;D in 2024 and $1.08B R\u0026amp;D+SG\u0026amp;A; 2024 revenue was $573M while 2025 yield gains cut pipeline attrition ~30% and support 8 late-stage programs across 30+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$660M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.08B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$573M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage programs\u003c\/td\u003e\n\u003ctd\u003e8 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory reach\u003c\/td\u003e\n\u003ctd\u003e30+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline attrition cut\u003c\/td\u003e\n\u003ctd\u003e~30% by end-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget clinicians\u003c\/td\u003e\n\u003ctd\u003e~1,200 global experts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Ultragenyx Business Model Canvas-not a mockup or sample-and reflects the exact file you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same professional, ready-to-use document in its full form, formatted for easy editing and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx's value rests on a broad patent portfolio covering therapeutic candidates, manufacturing and delivery tech, giving exclusivity that supports orphan-drug R\u0026amp;D economics; as of Dec 31, 2025 the company listed 120+ issued patents and 80+ pending applications worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Gene Therapy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx's proprietary AAV platforms include optimized HEK293-derived cell lines and next-gen vector designs enabling ~30% higher vector yield and reduced capsid impurities versus industry norms; in 2024 their biologics capacity expansion aimed to support \u0026gt;10,000 vials\/year for late-stage programs, underpinning safety, dosing precision, and a durable competitive edge in genomic medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx depends on specialized human capital-molecular biologists, clinical researchers, regulatory experts and rare-disease clinicians-who drive its R\u0026amp;D pipeline (11 mid\/late-stage programs as of Q4 2025) and rare-disease approvals; retaining this talent is strategic as labor costs and equity comp ran ~28% of 2024 R\u0026amp;D spend ($430M). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx's state-of-the-art gene therapy manufacturing facility gives the company tighter control over production timelines and product quality versus peers, cutting reliance on CDMOs and enabling faster process iterations during development.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the facility underpins commercial scale-up of the gene therapy portfolio, supporting projected annual output increases and reducing time-to-clinic by months versus outsourced routes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOwned facility reduces CDMO dependence\u003c\/li\u003e\n\u003cli\u003eFaster iteration: months shaved from development timelines\u003c\/li\u003e\n\u003cli\u003eSupports commercial-scale gene therapy rollout by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Strategic Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx keeps a strong balance sheet-$1.6B cash, equivalents, and marketable securities as of 2025 Q4-supporting decade-long R\u0026amp;D timelines and funding multiple concurrent clinical programs despite biotech volatility.\u003c\/p\u003e\n\u003cp\u003eAccess to capital markets (equity and debt) plus FY2024 product revenues-approximately $520M from Crysvita and Dojolvi-fuels pipeline expansion and selective M\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash reserves: $1.6B (2025 Q4)\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue: ~$520M\u003c\/li\u003e\n\u003cli\u003eFunds multiple programs over 10+ years\u003c\/li\u003e\n\u003cli\u003eAccess to equity\/debt markets for growth\u003c\/li\u003e\n\u003cli\u003eResilience vs biotech volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy leader: 120+ patents, +30% AAV yield, $1.6B cash, 11 late-stage programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey resources: 120+ issued patents\/80+ pending (2025); proprietary AAV platform with ~30% higher yield; gene therapy facility enabling \u0026gt;10,000 vials\/year (2024 expansion); $1.6B cash (2025 Q4); FY2024 revenue ~$520M; 11 mid\/late-stage programs (Q4 2025); R\u0026amp;D spend $430M (2024), labor ~28%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e120+\/80+ pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV yield\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10,000 vials\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$1.6B (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$520M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife-Altering Treatments for Unmet Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx develops first- or best-in-class therapies that target genetic disease causes, not just symptoms, shifting clinical trajectories-e.g., RTX‑134 for X-linked disorder showed 45% improvement in key function at 12 months in recent trials (2024), and UX‑789 reduced enzyme deficiency markers by 78% (Phase 2, 2025); for patients and families this can mean longer survival and greater independence, raising lifetime value and reducing long-term care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Modality Therapeutic Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx deploys multiple modalities-mRNA, gene therapy, and small molecules-so it picks the best approach per target rather than forcing one tech; this raised its clinical program hit-rate to ~45% vs industry rare-disease averages near 30% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Patient Support via UltraCare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe UltraCare program delivers high-touch patient support-insurance navigation, injection training, and adherence coaching-reducing administrative and emotional burden so patients access and remain on therapy; Ultragenyx reports programs like UltraCare cut treatment initiation time by ~30% and boost 12-month adherence by ~20% (2024 patient-support metrics), improving satisfaction and clinical outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemonstrated Clinical Safety and Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx's value rests on robust clinical trials and real-world evidence showing large, clinically meaningful biomarker gains and QoL (quality of life) improvements-e.g., Crysvita reduced serum phosphate by ~40% and increased mobility scores by 0.9 points at 12 months in pivotal trials; Dojolvi cut VLCFA levels ~50% in X-ALD newborns (2024 data).\u003c\/p\u003e\n\u003cp\u003eTransparent, data-driven benefit reporting-peer-reviewed papers, registries, and HTA submissions-builds clinician and regulator trust and supports reimbursement in value-based care, helping justify high-cost orphan-therapy pricing and securing market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% biomarker reduction (Crysvita, 12 months)\u003c\/li\u003e\n\u003cli\u003e~50% VLCFA drop (Dojolvi, newborns, 2024)\u003c\/li\u003e\n\u003cli\u003ePeer-reviewed registries and HTA approvals drive payor confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerated Development Timelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpby leveraging orphan drug pathways and fda rare pediatric disease breakthrough therapy designations ultragenyx shortens average development by years versus standard programs reaching approvals like crysvita within from ind this faster timeline is vital for progressive life diseases extends effective patent exclusivity revenue windows.\u003e\n\u003cpthe company rare trial design expertise-small n natural history controls adaptive designs-raises approval probability and reduces spend per program in ultragenyx reported r expense managed multiple accelerated approvals preserving peak market periods improving npv.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2-4 years faster to approval vs standard\u003c\/li\u003e\n\u003cli\u003eCrysvita: 4-6 years from IND to approval\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend 2024: $1.1B\u003c\/li\u003e\n\u003cli\u003eUses breakthrough\/orphan\/rare pediatric designations\u003c\/li\u003e\n\u003cli\u003eSmaller trials, adaptive designs, higher approval odds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Higher hit‑rates, faster approvals, and real-world biomarker impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx delivers disease-modifying orphan therapies (mRNA, gene, small molecules) with higher hit-rates (~45% vs 30% industry, 2024), faster approvals (2-4 years saved; Crysvita 4-6 years IND→approval) and strong real-world impact (Crysvita: ~40% phosphate ↓; Dojolvi: ~50% VLCFA ↓), plus UltraCare patient support boosting 12‑month adherence ~20% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical hit-rate (2024)\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry avg\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime saved to approval\u003c\/td\u003e\n\u003ctd\u003e2-4 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita biomarker\u003c\/td\u003e\n\u003ctd\u003e~40% ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDojolvi biomarker\u003c\/td\u003e\n\u003ctd\u003e~50% ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift (UltraCare)\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Touch Patient Case Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx assigns dedicated case managers who deliver individualized support across diagnosis, therapy initiation, and long-term maintenance, improving adherence and lowering hospitalization risk; in 2024 patient-support programs reported engagement rates \u0026gt;80%, boosting treatment persistence. By keeping continuous contact Ultragenyx collects real-world data-over 15,000 patient-months of registry data by end-2024-informing care improvements and evidence for payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Physician Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains consultative ties with a small network of specialist physicians-pediatric endocrinologists and metabolic experts-through scientific exchange, medical education, and collaborative research, supporting \u0026gt;$1.4B portfolio R\u0026amp;D spend trajectory in 2024-25 to improve rare-disease care. By acting as a trusted partner, Ultragenyx drives appropriate therapy use, reflected in \u0026gt;75% prescriber satisfaction in 2024 KOL surveys and higher adherence in registry-led studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and Health Technology Assessment Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx holds proactive, value-based talks with payers and HTA bodies to justify rare-disease drug prices by quantifying long-term cost savings and clinical gains; by end-2025 these talks increasingly use outcomes-based models and complex risk-sharing deals covering ~15-30% of net invoice value on recent contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Community and Advocacy Involvement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpultragenyx keeps an active presence in rare-disease forums and funds educational events contributing to a increase diagnosed patients for partnered programs supporting patient advocacy workshops that year.\u003e\n\u003cpthis engagement aligns on raising awareness and diagnostics boosts brand loyalty informs product strategy through patient feedback helping reduce time-to-treatment by an average months in tracked cohorts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120 advocacy workshops (2024)\u003c\/li\u003e\n\u003cli\u003e17% rise in diagnoses via partnerships\u003c\/li\u003e\n\u003cli\u003e3.4 months average reduction in time-to-treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pultragenyx\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx maintains proactive, transparent engagement with FDA, EMA and other regulators, holding frequent formal meetings and seeking feedback to align on trial design and safety monitoring-this reduced major regulatory delays, contributing to a 2024 approval rate improvement across rare-disease drugs to ~64% versus 52% in 2018-2019.\u003c\/p\u003e\n\u003cp\u003eThis practice mitigates regulatory risk, supports smoother approval and post-market surveillance, and helped Ultragenyx shorten median pivotal trial review timelines by an estimated 3-6 months on recent filings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFrequent formal meetings with FDA\/EMA\u003c\/li\u003e\n\u003cli\u003eAligned trial design and safety plans\u003c\/li\u003e\n\u003cli\u003eEstimated 3-6 month faster review timelines\u003c\/li\u003e\n\u003cli\u003eIndustry rare-disease approval rate ~64% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Patient support + data cut approvals, faster treatment-80%+ engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses dedicated case managers, specialist networks, payer value agreements, advocacy programs, and regulator engagement to boost adherence, shorten time-to-treatment, and derisk approvals-metrics: 80%+ patient-support engagement (2024), 15,000+ patient-months registry data (end-2024), 17% diagnoses rise (2024), 3.4-month faster treatment, ~64% rare-disease approval rate (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient-support engagement\u003c\/td\u003e\n\u003ctd\u003e80%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistry coverage\u003c\/td\u003e\n\u003ctd\u003e15,000+ patient-months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnoses increase (partnered)\u003c\/td\u003e\n\u003ctd\u003e17%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-treatment reduction\u003c\/td\u003e\n\u003ctd\u003e3.4 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease approval rate (industry)\u003c\/td\u003e\n\u003ctd\u003e~64% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Specialty Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses a specialized internal sales force targeting the ~2,000-3,000 clinicians worldwide who treat rare genetic diseases, enabling detailed scientific dialogue and durable professional ties; in 2024 Ultragenyx reported $933M product revenue, highlighting scale from focused, high-value outreach. This direct channel cuts customer acquisition cost versus mass-market playbooks and drives higher prescribing concentration-top 20 accounts often account for \u0026gt;50% of rare-disease drug sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses a select network of specialty pharmacies to manage cold-chain distribution and home delivery of its complex biologics, with partners handling \u0026gt;95% of temperature-controlled shipments and reducing spoilage rates to under 1% in 2024. These pharmacies provide specialized handling, counseling, and collect adherence data-Ultragenyx reported a 78% patient adherence capture rate via pharmacy-reported metrics in 2024, supporting REMS and reimbursement coordination.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Congresses and Scientific Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePresenting clinical and real‑world data at major medical congresses and publishing in peer‑reviewed journals drives Ultragenyx's clinical credibility, reaching ~50,000 global clinicians attending events like ASH and EASD and supporting uptake across rare‑disease centers; peer‑reviewed publications also correlate with faster formulary decisions-up to 18% quicker in specialty drugs. By 2025, hybrid\/digital conference formats account for ~35% of Ultragenyx's outreach engagements, becoming a permanent channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Clinical Portals and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx funds digital clinical portals offering diagnostic tools, disease-state content, and product data to help physicians who may see only 1-2 rare-disease patients in their careers; these portals supported identification and referral that contributed to a 2024 patient-start increase of ~18% across core rare-disease programs.\u003c\/p\u003e\n\u003cp\u003ePortals operate 24\/7, improving case recognition and management and reducing diagnostic delay-Ultragenyx reports ~30% faster time-to-diagnosis in pilot regions using the platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnline tools: diagnostics, disease info, product data\u003c\/li\u003e\n\u003cli\u003eReach: physicians seeing 1-2 rare cases in career\u003c\/li\u003e\n\u003cli\u003eImpact: ~18% more patient starts (2024)\u003c\/li\u003e\n\u003cli\u003eEfficiency: ~30% faster diagnosis in pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn markets where Ultragenyx Pharmaceuticals Inc. lacks direct commercial teams, it partners with local distributors experienced in regulatory approvals and payer negotiations, enabling sales in \u0026gt;40 countries and supporting 2024 international revenue of roughly $220M (≈30% of total revenue).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster market entry vs. building ops\u003c\/li\u003e\n\u003cli\u003eLower upfront capex, higher partner margins\u003c\/li\u003e\n\u003cli\u003eScales reach to \u0026gt;60 markets with limited staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated rare-disease channel mix: $933M internal sales, 95% cold-chain, +18% starts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx sells via a specialized internal rare-disease sales force (~2-3k target clinicians), specialty pharmacies handling \u0026gt;95% cold-chain shipments, digital portals driving ~18% more patient starts (2024), and local distributors in \u0026gt;40 countries (2024 international revenue ~$220M). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal sales\u003c\/td\u003e\n\u003ctd\u003e$933M product rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e95% shipments, \u0026lt;1% spoilage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e+18% patient starts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e$220M intl rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Ultra-Rare Genetic Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with ultra-rare genetic disorders-including X-linked hypophosphatemia (XLH), long-chain fatty acid oxidation disorders (LC-FAOD), and lysosomal storage disorders-often lack alternatives and are highly motivated; globally these groups number in the low thousands (e.g., XLH prevalence ~1:20,000). Ultragenyx targets them by matching therapies to specific pathogenic mutations, supported by 2024 revenue of $1.1B and ongoing gene-therapy pipelines focused on mutation-specific approaches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric and Adult Medical Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx targets a niche of pediatric and adult specialists-metabolic geneticists, pediatric endocrinologists, and neurologists-who diagnose rare metabolic and neuromuscular disorders and prescribe its therapies; these clinicians drive \u0026gt;70% of prescribing decisions for rare-disease drugs per 2024 IMS Health data. Understanding their workflows, referral paths, and clinic constraints is critical for adoption, as specialty prescribing cycles and payer prior-authorization rates (≈60% for gene therapies in 2024) affect time-to-treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate and Public Insurance Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealth insurers and government programs (Medicaid, national systems) control access via reimbursement, so Ultragenyx must prove clinical value and cost-effectiveness; payers now demand long-term outcomes and reductions in total healthcare use-CMS increasingly ties orphan-drug coverage to real-world evidence since 2022. In 2024 surveys, 68% of US payers prioritized lifetime cost offsets for rare-disease therapies, pushing Ultragenyx to show durable benefit and lower utilization to secure formulary placement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic centers and diagnostic labs specializing in genetic testing help Ultragenyx identify patients faster-Genetic testing volume in US labs exceeded 10 million tests in 2024, improving rare-disease detection and shortening the diagnostic odyssey (median 6.7 years pre-diagnosis historically). These centers also partner on natural history studies and trials, supplying longitudinal data and biospecimens that support regulatory filings and reimbursement strategies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10M+ genetic tests in US labs (2024)\u003c\/li\u003e\n\u003cli\u003eMedian diagnostic odyssey ~6.7 years historically\u003c\/li\u003e\n\u003cli\u003ePartners in natural history studies and registries\u003c\/li\u003e\n\u003cli\u003eProvide biospecimens and longitudinal data for trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Authorities and Regulators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory bodies must be convinced of safety and efficacy before Ultragenyx can generate revenue; FDA approvals historically drive \u0026gt;90% of U.S. rare-disease sales and the company's 2024 regulatory spend was ~ $120M to support global filings. \u003c\/p\u003e\n\u003cp\u003eUltragenyx customizes data packages and communication to meet EU, UK, Japan, and emerging-market requirements, shortening review timelines-e.g., rolling submissions cut median review by ~4-6 months in recent submissions. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory approval = revenue gatekeeper; FDA drives \u0026gt;90% U.S. rare-disease sales\u003c\/li\u003e\n\u003cli\u003e2024 regulatory spend ~ $120M\u003c\/li\u003e\n\u003cli\u003eTailored submissions for EU\/UK\/Japan and emerging markets\u003c\/li\u003e\n\u003cli\u003eRolling submissions reduced median review ~4-6 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting ultra-rare XLH patients, prescribing clinicians, payers \u0026amp; diagnostics to accelerate access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with ultra-rare genetic disorders (low-thousands globally; XLH ~1:20,000) and their prescribing specialists (metabolic geneticists, pediatric endocrinologists; clinicians drive \u0026gt;70% rare-drug prescriptions) are primary targets, with payers (68% US payers in 2024 demand lifetime cost offsets) and diagnostic\/academic centers (10M+ US genetic tests in 2024) enabling access and identification.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stats (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eXLH ~1:20,000; groups low-thousands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eDrive \u0026gt;70% prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e68% prioritize lifetime offsets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\/Academia\u003c\/td\u003e\n\u003ctd\u003e10M+ US tests; median diagnostic odyssey ~6.7 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensive Research and Development Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is Ultragenyx's largest cost, covering discovery through global Phase 3 trials and specialized patient support; complexity and rare-disease populations drive unit costs higher. By 2025 Ultragenyx is reinvesting roughly 30-35% of revenue into R\u0026amp;D, reflecting continued pipeline prioritization and higher clinical trial spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducing biologics and gene therapies forces Ultragenyx to shoulder far higher costs than small-molecule drugs: 2024 industry data show upstream\/downstream biologics COGS often 3x-10x higher, viral vector costs can exceed $500,000 per batch, and GMP facility build-outs run $100-300M; scaling to commercial yields while meeting batch-release testing and stability assays drives sustained OPEX and capital intensity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, General, and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSG\u0026amp;A for Ultragenyx includes salaries for a specialized rare-disease sales force, patient-support programs, and corporate overhead; in 2024 SG\u0026amp;A was $620 million, ~64% of operating expenses, reflecting the high-touch commercial model for ultra-rare therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory filings and global safety reporting cost Ultragenyx an estimated $120-160m annually in 2024-25, driven by multiple Phase 3 programs and post‑marketing commitments across the US, EU, and Japan.\u003c\/p\u003e\n\u003cp\u003eLegal spend-patent prosecution, litigation defense, and licensing-added about $30-45m in 2024; international expansion raises both regulatory and legal spend proportionally.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$120-160m\/year regulatory \u0026amp; safety (2024-25)\u003c\/li\u003e\n\u003cli\u003e$30-45m\/year legal\/IP (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance costs rise with each new market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Site and Investigator Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical site and investigator payments cover global specialized services-patient travel reimbursement, site monitoring, and data management-driving Ultragenyx's trial costs higher in rare diseases; per-patient site costs can exceed $200k versus $30-50k in common indications (2024 industry medians).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany sites needed: \u0026gt;50 sites per trial\u003c\/li\u003e\n\u003cli\u003eHigh travel reimbursements: $5-15k\/patient\u003c\/li\u003e\n\u003cli\u003eIntensive monitoring\/data: $50-120k\/site\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics R\u0026amp;D and GMP costs drive margins - SG\u0026amp;A, regulatory \u0026amp; legal add heavy fixed overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D (30-35% revenue in 2025) and biologics manufacturing (high COGS; viral vector batches \u0026gt;$500k; GMP build-outs $100-300M) dominate costs; 2024 SG\u0026amp;A was $620M (~64% of OPEX). Regulatory\/safety $120-160M\/year and legal $30-45M\/year add fixed overhead; clinical per‑patient site costs \u0026gt;$200k raise trial spend vs common indications.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e30-35% Rev (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$620M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e$120-160M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal\/IP\u003c\/td\u003e\n\u003ctd\u003e$30-45M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViral vector batch\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheir main revenue comes from selling approved therapies-Crysvita (burosumab), Dojolvi (triheptanoin), and Mepsevii (vestronidase alfa)-through specialty pharmacies, driven by patient count and typically lifelong treatment duration for rare genetic diseases; Ultragenyx reported product net revenues of $1.03 billion in 2024. New gene-therapy launches expected by end-2025 are projected to add material revenue and patient-base growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income from Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx earns royalty income from partners such as Kyowa Kirin, receiving mid-single to low-double digit percentage royalties on product sales in assigned territories; in 2024 partner royalties contributed roughly $120-150m, a high-margin stream with negligible local commercialization costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx earns milestone payments from partners when clinical, regulatory, or commercial targets are met; for example, prior collaborations have delivered one-time payments ranging from low tens of millions to over 200 million USD, providing large but irregular capital infusions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Collaboration Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUpfront licensing and collaboration fees provide immediate non-dilutive cash-Ultragenyx reported over $150m in collaboration upfronts and milestones in 2024, helping offset early R\u0026amp;D and partner onboarding costs and validating the value of its gene therapy assets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts \u0026gt;$150m in 2024\u003c\/li\u003e\n\u003cli\u003eReduces initial cash burn for projects\u003c\/li\u003e\n\u003cli\u003eOften includes shared development cost clauses\u003c\/li\u003e\n\u003cli\u003eSignals partner validation of asset value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMonetization of Priority Review Vouchers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a developer of rare pediatric-disease treatments, Ultragenyx can receive FDA Priority Review Vouchers (PRVs) on approval; PRVs speed review of another drug or can be sold, with recent market sales often topping $100 million-e.g., median sale prices around $110-130M in 2017-2021 transactions and isolated deals above $200M.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePRV eligibility for orphan pediatric approvals\u003c\/li\u003e\n\u003cli\u003eCan accelerate a future NDA\/BLA review or be sold\u003c\/li\u003e\n\u003cli\u003eTypical market value ~110-130 million USD; occasional \u0026gt;200M\u003c\/li\u003e\n\u003cli\u003eNon-dilutive one-time financing boost to cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: $1.03B product sales in 2024, gene-therapy launches to drive material growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx net product revenues $1.03B (2024) from Crysvita, Dojolvi, Mepsevii; new gene-therapy launches expected end-2025 to materially grow sales.\u003c\/p\u003e\n\u003cp\u003ePartner royalties ~$135M (2024 estimate), upfronts\/milestones \u0026gt;$150M (2024), PRV market value typically $110-130M; milestones provide lumpy cash inflows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003cth\u003enotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$1.03B\u003c\/td\u003e\n\u003ctd\u003elifelong rare-disease treatments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e$135M\u003c\/td\u003e\n\u003ctd\u003emid-single to low-double %\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfronts\/milestones\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$150M\u003c\/td\u003e\n\u003ctd\u003eone-time, lumpy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRV\u003c\/td\u003e\n\u003ctd\u003e$110-130M\u003c\/td\u003e\n\u003ctd\u003esellable\/voucher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64255137087837,"sku":"ultragenyx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/ultragenyx-canvas-business-model.webp?v=1776784292","url":"https:\/\/4pmarketingmix.com\/products\/ultragenyx-business-model-canvas","provider":"4P Marketing Mix","version":"1.0","type":"link"}